AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32720608
Drug: Levofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (750 mg IV daily for at least 7 days)
Trial: 32320006
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1000 mg/d for 6 weeks
Trial: 32698144
Drug: Genetically instrumented
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically instrumented TSH (approximately 0.8 mIU/L)
Trial: 33565893
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray plus oral antidepressant (ESK + oral AD)
Trial: 33565893
Drug: Oral antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidepressant plus nasal placebo (oral AD + PBO)
Trial: 33823606
Drug: Dual-therapy sirolimus-eluting
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS)
Trial: 36178946
Drug: Real US-guided
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real US-guided dry needling with exercise therapy (G1)
Trial: 36178946
Drug: Placebo US-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo US-guided dry needling with exercise therapy (G2)
Trial: 36178946
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy solely (G3)
Trial: 32169925
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (CL) insulin delivery for 24 months
Trial: 32169925
Drug: Standard multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multiple daily injections (MDI) therapy for 24 months
Trial: 36450940
Drug: 200-mg testosterone
RxNorm normalized name: testosterone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg testosterone enanthate/wk (TEST)
Trial: 35713950
Drug: Progesterone 200
RxNorm normalized name: progesterone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone 200 mg daily
Trial: 34435933
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of tetravalent measles-mumps-rubella-varicella vaccine (V2 group)
Trial: 34435933
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose trivalent measles-mumps-rubella (MMR) vaccine and one dose of varicella vaccine (V1 group)
Trial: 34435933
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MMR vaccine (V0 group, control)
Trial: 33827700
Drug: Calcitriol treatment
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol treatment (0.25 mcg/day for 4 months)
Trial: 33827700
Drug: Calcitriol treatment
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol treatment (0.25 mcg/day for 4 months) in patients with Ff genotype
Trial: 34007434
Drug: Operating room
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Operating room nursing intervention combined with traditional treatment methods
Trial: 34007434
Drug: Traditional nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional nursing combined with traditional treatment
Trial: 34463805
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia group (spinal fentanyl followed by oral tramadol, paracetamol, and diclofenac every 6 hours for 48 hours)
Trial: 34463805
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine group (spinal morphine followed by oral tramadol, paracetamol, and diclofenac)
Trial: 33020005
Drug: 6 educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 educational sessions, parent feedback via the Communication Assessment Tool (CAT), monthly communication tips
Trial: 34197699
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication therapy monitoring and management via a smartphone-enabled mHealth app
Trial: 34821175
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (cisplatin with pemetrexed)
Trial: 34821175
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (cisplatin with pemetrexed)
Trial: 34895064
Drug: Mindfulness-Based Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive-Behavioral Sex Therapy (MBCST)
Trial: 35817672
Drug: Bivalirudin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion, adjusted to maintain ACT >480 s)
Trial: 35817672
Drug: Bivalirudin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (1 mg/kg bolus followed by 2.2 ± 0.4 mg/kg/h infusion)
Trial: 32151792
Drug: Illusory patterns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illusory patterns with vertically aligned white dots in L shape
Trial: 32151792
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of T shape vs L shape configurations
Trial: 32428786
Drug: Exercise training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training, nutritional education, and medication reconciliation for 5.1 ± 0.6 months
Trial: 35616942
Drug: Spermidine supplementation
RxNorm normalized name: spermidine
DrugBank: Spermidine (DB03566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermidine supplementation (0.9 mg spermidine/d) for 12 months
Trial: 33564824
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (800 µg daily for 3 years)
Trial: 35173154
Drug: amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin + cefotaxime
Trial: 35173154
Drug: non-antibiotic treated
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-antibiotic treated infants (control group)
Trial: 34480008
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with HI warm-up
Trial: 34480008
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with LI warm-up
Trial: 36147018
Drug: CBMT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBMT + TAU (Cognitive Bias Modification Training + Treatment as Usual)
Trial: 35212286
Drug: Synbiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (Bifidobacterium longum NT strain 1010 CFU/day and galactooligosaccharide 1 g/day)
Trial: 32561467
Drug: Narrative Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Exposure Therapy (NET) addressing PTSD
Trial: 32561467
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse
Trial: 34330458
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid (UA) supplementation (450 mg/day)
Trial: 33048901
Drug: Light sedation
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light sedation with a daily wake‐up call
Trial: 36163254
Drug: Methylphenidate (MP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP; 60 mg)
Trial: 32087001
Drug: Cenobamate single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate single-dose (5 to 750 mg)
Trial: 32087001
Drug: Cenobamate multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate multiple-dose (50 to 600 mg/day)
Trial: 32087001
Drug: Cenobamate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (all doses)
Trial: 32087001
Drug: Cenobamate (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (multiple daily doses of 600 mg)
Trial: 36017875
Drug: Obinutuzumab consolidation
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab consolidation therapy
Trial: 33587687
Drug: Ad26.ZIKV.001 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZIKV.001 (1 × 10^11 vp, 1-dose regimen)
Trial: 616670476
Drug: Volumetric-modulated arc
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volumetric-modulated arc therapy (VMAT)
Trial: 33373701
Drug: Paracetamol (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1g intravenous infusion)
Trial: 33373701
Drug: Parecoxib (40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40mg intravenous infusion)
Trial: 32787809
Drug: Self-management behaviors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management behaviors (medication therapy, diet therapy, exercise, tobacco and alcohol avoidance, stress reduction, self-monitoring/self-care)
Trial: 32787809
Drug: Self-management behaviors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management behaviors (diet therapy)
Trial: 32787809
Drug: Self-management behaviors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management behaviors (medication therapy)
Trial: 35486131
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid in combination with ezetimibe
Trial: 35623877
Drug: Morus Alba
RxNorm normalized name: MORUS ALBA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morus Alba extract (300 mg)
Trial: 32579195
Drug: Colchicine with
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine with standard medical treatment
Trial: 33471547
Drug: Progressive active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive active exercise therapy (PR)
Trial: 33471547
Drug: Limited passive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited passive exercise therapy (UC)
Trial: 32540337
Drug: Cetuximab consolidation
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab consolidation (500 mg/m2 biweekly × 6)
Trial: 32966574
Drug: RBX7455 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX7455 (4 capsules twice daily for 4 days)
Trial: 32966574
Drug: RBX7455 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX7455 (4 capsules twice daily for 2 days)
Trial: 32966574
Drug: RBX7455 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX7455 (2 capsules twice daily for 2 days)
Trial: 35107188
Drug: Colchicine in
RxNorm normalized name: colchicine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine in combination with standard care
Trial: 34062263
Drug: Polyphenols as
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenols as adjunctive treatments
Trial: 32769849
Drug: CMX-2043 (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX-2043 (2.4 mg/kg)
Trial: 36197656
Drug: Completely successful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completely successful belief about antibiotics
Trial: 36197656
Drug: Intermediate belief
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate belief about antibiotics
Trial: 33517830
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of influenza vaccine availability
Trial: 33517830
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of free influenza vaccine availability
Trial: 33517830
Drug: Confidence in
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence in vaccine efficacy
Trial: 33517830
Drug: Confidence in
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence in vaccine safety
Trial: 32835919
Drug: Fennel seed
RxNorm normalized name: FENNEL SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fennel seed extract (200 mg per capsule, 4 capsules daily for 2 weeks)
Trial: 32835919
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules daily for 2 weeks)
Trial: 34110580
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution (RLS)
Trial: 32876695
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg IV daily for 5 days or 10 mg IV daily for 5 days until ICU discharge) plus standard care
Trial: 33168504
Drug: Conventional circumcision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional circumcision (CC)
Trial: 34556856
Drug: Valsartan (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (320 mg daily in adults; 80-160 mg daily in children)
Trial: 35345654
Drug: Dexmedetomidine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine combined intravenous anesthesia
Trial: 35345654
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous anesthesia
Trial: 32161953
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ketone bodies during a hyperinsulinemic-euglycemic clamp
Trial: 32161953
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of saline during a hyperinsulinemic-euglycemic clamp
Trial: 34089846
Drug: Lirentelimab (AK002),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirentelimab (AK002), an antibody against siglec-8 that depletes eosinophils and inhibits mast cells.
Trial: 35230440
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy after TURBT
Trial: 32028974
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg intravenously on day 1 and gemcitabine 1000 mg/m2 intravenously on days 1 and 8 every 21 days until disease progression or unacceptable toxicity
Trial: 32028974
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and gemcitabine combination therapy
Trial: 33827091
Drug: 4 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L/min bias gas flow
Trial: 33827091
Drug: 10 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 L/min bias gas flow
Trial: 32889867
Drug: Sirolimus for
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus for ≥3 months after LT for HCC in patients with AFP ≥10 ng/mL
Trial: 33994886
Drug: CN injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CN injection group
Trial: 32924553
Drug: Acupuncture Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture Therapy (AT)
Trial: 35639946
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (no infiltration, subcutaneous infiltration, rectus sheath infiltration)
Trial: 32154936
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus aspirin (90 mg twice daily plus 100 mg once daily)
Trial: 32154936
Drug: Ticagrelor alone
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor alone (90 mg twice daily)
Trial: 32154936
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (100 mg once daily)
Trial: 32475312
Drug: Sodium reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium reduction with slow sodium tablets for 6 weeks
Trial: 32475312
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 6 weeks
Trial: 34138875
Drug: Group Problem
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Problem Management Plus (PM+), a psychological treatment of 5 weekly sessions
Trial: 33357420
Drug: Intravenous pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous pertuzumab (840 mg loading dose, followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses)
Trial: 33357420
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses)
Trial: 33592837
Drug: Heat patch
RxNorm normalized name: CVS Body Heat Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat patch on acupuncture points during the follicular phase (Group C, n=15)
Trial: 34475522
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of saracatinib
Trial: 34475898
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (NOT) with intravenous Meropenem and Metronidazole for 48 hours followed by oral antibiotics for 7 days (Group A)
Trial: 34475898
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (NOT) with failure
Trial: 33969450
Drug: UV-irradiated implants
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-irradiated implants
Trial: 33969450
Drug: Conventional commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional commercial implants
Trial: 35801618
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) treatment by inexperienced physicians
Trial: 35801618
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) treatment by experienced physicians
Trial: 32345329
Drug: PE +
RxNorm normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE + Peer Support (weekly peer calls for 3-4 weeks)
Trial: 34125980
Drug: Cigarette smoke
RxNorm normalized name: cigarette smoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoke extract (CSE) treatment in 16HBE cells
Trial: 33279373
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment (MT)
Trial: 33279373
Drug: Dose-reduction/discontinuation (DR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduction/discontinuation (DR)
Trial: 35442091
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - multicomponent national child oral health improvement intervention (Childsmile program) excluding nursery FV
Trial: 32611327
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant radiotherapy (RT) in addition to standard postoperative treatment of HBV/HCV and nutritional therapy
Trial: 32611327
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment of HBV/HCV and nutritional therapy (Control)
Trial: 36297080
Drug: L-Citrulline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline (10 g)
Trial: 33993905
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Secukinumab 75 mg, 150 mg, 300 mg)
Trial: 35581905
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pioglitazone plus exenatide